PRESS RELEASE

Tarveda Therapeutics to Present at Raymond James Life Sciences and MedTech Conference

WATERTOWN, MA, June 11, 2019 – Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing a new class of potent and selective precision oncology medicines for the treatment of patients with a wide range of solid tumor malignancies, today announced that Drew Fromkin, President and Chief Executive Officer, will present at the Raymond James Life Sciences and MedTech Conference occurring June 18-19, 2019 in New York City. Tarveda presentation details:

Date: Tuesday, June 18, 2019
Time: 8:00am Eastern Time
Location: Lotte New York Palace, New York, NY

About Tarveda Therapeutics, Inc.
Tarveda Therapeutics is a clinical stage biopharmaceutical company that is developing and discovering a new class of potent and selective precision oncology medicines for the treatment of patients with solid tumor malignancies. We are developing our proprietary Pentarin® miniature conjugates to enhance the effectiveness of promising anti-cancer payloads by selectively binding them to desired tumor targets where they accumulate.  www.tarvedatx.com

Contact:
Amanda Houlihan
MacDougall 
781 235 3060 
ahoulihan@macbiocom.com